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ABSTRACT: Polyethylene glycols (PEGs) are commonly employed as excipients in preclinical studies 
and in vitro experiments to dissolve poorly hydrosoluble drugs. Their use is generally considered safe 
in both animals and humans; however, limited data is available concerning the safety of PEGs when 
administered parenterally. The results of our investigation demonstrate that PEG-400 can have an 
irritant effect on serosal surfaces and causes subcapsular hepatocellular necrosis in mice when 
administered intraperitoneally at a high dose. Accordingly, levels of serum biomarkers of liver injury 
need to be carefully interpreted in studies where PEG is administered intraperitoneally and always in 
association with the results of the histological assessment. 
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1. INTRODUCTION 
Polyethylene glycols (PEGs) comprise a class of synthetic polymers composed of identical ethylene 
oxide subunits, with molecular weights varying between 200 and 10,000. PEGs are known for their 
versatile range of industrial applications and are ideal candidates for the development of solvents, 
vehicles and emulsifying agents in the pharmaceutical and cosmetic industries (Fruijtier-Pölloth, 2005). 
In addition, PEGylation of therapeutic products has become in the last two decades an attractive and 
effective tool to modulate the pharmacological properties of drugs, such as solubility, stability and 
immunogenicity, and to improve their metabolic and toxicological profiles (Pasut et Veronese, 2011).  
Due to their extensive use and the potential chronic exposure of humans through different routes, the 
acute and repeat dose toxicity of PEGs has been widely investigated in several preclinical species. 
PEGs and pegylated products generally have excellent safety profiles, with toxicity occurring only with 
high parenteral doses that far exceed the concentrations normally used in practice (Fruijtier-Pölloth, 
2005). 
Due to the strong hydrophilic properties, low molecular weight PEGs, such as PEG-400, have been 
used in non-clinical studies to deliver poorly hydrosoluble drugs by different routes, including 
intraperitoneal (ip) administration (Gad et al., 2006; Rowe et al., 2009).Limited data concerning dosing 
regimens and safety of PEGs injected directly into the abdominal cavity are available, as this route of 
administration is not commonly used in humans. Studies investigating the acute ip toxicity of low 
molecular weight PEGs in mice determined a LD50 of 9.2 g/kg and a NOEL (“no observed effect level”) 
of 1 ml/kg (Shideman et Procita, 1951; Worthley et Schott, 1966; Rowe et al., 2009). No assumption 
has been made regarding the cause of death of mice administered an ip lethal dose of PEG, but it is 
likely this could be attributed to a rapidly developing hypovolaemic shock. This assumption is 
supported by the fact that, given ip at high doses (between 3.5 g/kg and 8 g/kg), PEG induces a 



































































it has been used in an experimental model of hypovolaemia in rats and mice (Fitzsimons, 1961; Dunn 
et al., 1973; Hashimoto et al., 2010).  
At our facilities, PEG-400 has been employed as a suitable ip vehicle in a murine model of 
hepatotoxicity induced by furosemide (FS) (Williams et al., 2007). As anticipated, FS caused extensive 
centrilobular hepatocellular necrosis, associated with substantial increases in alanine aminotransferase 
(ALT) serum activity and raised levels of circulating micro-RNA (MiR-122); however, we also observed 
biomarker levels above normal historical background ranges in several vehicle-control (PEG-400) mice. 
Furthermore, a few vehicle-control mice also exhibited multifocal subcapsular hepatic necrosis. These 
changes complicated the interpretation of drug-related biomarker increases and prompted an 
investigation to elucidate the relationship between the observed changes and PEG-400 application. 
 
2. METHODS 
2.1 Study animals and procedures 
The protocols described were undertaken in accordance with criteria outlined in a license granted 
under the Animals (Scientific Procedures) Act 1986 and approved by the University of Liverpool Animal 
Ethics Committee. All animals were obtained from Charles River (Margate, UK). 
Retrospective analysis of the controls from furosemide toxicity studies at our facility identified 60 male 
and female CD-1 and C57BL6 mice (5-7 weeks old, 25–35 g at study start) that had received a single 
ip injection of PEG-400 (density: 1.126 g/mL) at 4 mL/kg of body weight. Animals had been killed with a 
raising concentration of carbon dioxide, followed by exsanguination by cardiac puncture at 1, 5, 8 or 24 
h post treatment. A complete gross post mortem examination had been performed on each mouse, 
gross abnormalities recorded and all tissues collected in 10% non-buffered formalin for histological 
analysis. Further studies using the same conditions and procedures described earlier were conducted 
on 15 male CD-1 mice to investigate the effect of different PEG-400 formulations (Sigma-Aldrich and 
Fischer) and the effect of PEG-400 at early time points (1, 3 and 5 h) post ip administration. The pH of 
the formulations was checked to be between 7.3 and 7.6 prior to administration. The formulations were 
certified for purity and identity by the manufacturers, which guarantee that the levels of residual 



































































mice euthanased 1, 3 and 5 h after treatment, portions of subcapsular hepatic parenchyma from 
different lobes were rapidly removed and fixed in 2.5% gluteraldehyde in 0.1M sodium cacodylate 
buffer (pH 7.4) for transmission electron microscopy (TEM). 
2.2 Determination of serum alanine transaminase activity and circulating MiR-12 
Blood samples were stored at 4°C and allowed to clot overnight. Serum was obtained from separation 
by pulse centrifugation (4000 rpm). Alanine transaminase activity (ALT) was determined in all animals 
using ThermoTrace Infinity ALT Liquid stable reagent according to the manufacturer's instructions. In 
12 male CD-1 mice euthanased at 5 and 8 h after PEG administration, miRNA levels were measured 
using a Taqman-based quantitative polymerase chain reaction (PCR), as previously described (Antoine 
et al., 2009). 
2.3 Histological, immunohistological and ultrastructural examination 
From all animals, multiple sections from the left and median hepatic lobes were prepared from formalin-
fixed livers. From the 15 animals euthanased at 1, 3, 5 and 8 hours post treatment, sections of the 
gastrointestinal tract (glandular and non glandular stomachs, duodenum, jejunum, ileum, caecum and 
colon), mesenteric lymph node, mesentery, spleen, kidneys, diaphragm, pancreas and the injection site 
(ventral abdominal muscle wall) were also formalin-fixed and processed. After routine paraffin wax 
embedding, sections (3-5 μm) were prepared and stained with haematoxylin and eosin. Selected liver 
sections were also stained with a Martius Scarlett Blue stain for the detection of fibrin and/or the 
Masson trichrome stain to highlight the connective tissue of the Glisson’s capsule. 
The extent of hepatocellular subcapsular necrosis was graded (grade 0-4), with 0: no changes or a 
negligible proportion of parenchyma affected; 1: focal or patchy single layer-deep subcapsular 
hepatocyte necrosis with occasional neutrophils; 2: multifocal, one or two layer-deep hepatocyte 
necrosis, surrounded by a thin continuous rim of neutrophils; 3: multifocal or diffuse, several layer-deep 
subcapsular hepatocyte necrosis with marked neutrophil infiltration; 4: diffuse subcapsular coagulative 




































































Immunohistology for the demonstration of TNF-α, IL-6, cleaved caspase 3 and proliferating cell nuclear 
antigen (PCNA) was performed on selected CD-1 mice euthanased at 3, 5, 8 and/or 24 h after dosing, 
following previously described protocols (Antoine et al., 2009). 
For TEM, fixed liver sections of selected CD-1 mice euthanased at 1, 3 and 5 h after dosing were 
routinely epoxy resin embedded. 3 µm toluidine blue stained semithin sections were used to select 
representative areas for 75 nm ultrathin sections, which were contrasted with uranyl acetate and lead 
citrate. 
2.4 Assessment of PEG-induced cytotoxicity in primary murine and human hepatocytes.  
Human Hep G2 and murine Hepa1c1c7 cells were used as test cell lines to assess the cytotoxicity of 
PEG-400 at varying concentrations. Both cell lines were maintained in Dulbecco’s Modified Eagles’ 
Medium (DMEM) containing glucose, L-glutamine, sodium pyruvate and sodium bicarbonate, 
supplemented with 10% foetal bovine serum and 1% penicillin streptomycin in T75 cell culture flasks 
and incubated for a minimum of 18 h in 96 well plates prior to incubation with PEG-400. Cells were 
dosed with PEG-400 in eight different concentrations, ranging from 0 to 750 µM (0-30% concentration). 
Three wells per plate were incubated with 250 µM of the antidepressant nefazodone, a known 
hepatotoxin, as positive controls. Plates were incubated for a period of 3, 5 or 24 h and subsequently 
tested for cell viability by (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTS) and ATP 
assays, according to the manufacturer’s instructions. 
 
3. RESULTS 
3.1 In vivo studies 
ALT levels were above the reference intervals cited in the literature (Loeb et Quimby, 1999) in 45% of 
mice receiving PEG-400, regardless of sex and strain. Biomarker increases occurred in mice 
euthanased at 5 and, more consistently, 8 h after dosing, where almost half of the cohort had serum 
levels ranging from just above the mean reference to 8 fold increases (Figure 1A). Circulating miR-122 
levels were determined in 12 examined mice. These were within our historical background reference 



































































examined exhibited increased levels above this limit. These were associated with increased ALT serum 
levels (Figure 1B). 
Post mortem examinations revealed ascites with up to 600 μl of clear transparent fluid in mice 
euthanased at 1 or 3 h after dosing, against a maximum volume of 200 μl of PEG-400 administered 
into the abdominal cavity. No other macroscopical changes were detected.  
The main histological finding was hepatocellular subcapsular necrosis. This was observed to a variably 
degree in 63% (n=47) of the mice (Figure 2). Necrosis was detected at all time points after 1 h post 
dosing, with an increase in incidence and severity from 5 to 8 h time points, while no appreciable 
difference was noted between the 8 and 24 h cohorts (Table 1). Histopathological scores were not 
influenced by gender, mouse strain or the formulation used.  
The subcapsular hepatocellular necrosis was focal to multifocal, patchy or extensive (involving almost 
the entire liver section). It affected one to several hepatocyte layers beneath the Glisson’s capsule. 
Necrotic hepatocytes were lined by scattered to large numbers of degenerate (karyorrhectic) 
neutrophils, accompanied by extravasated erythrocytes. Above subcapsular necrotic areas, small 
amounts of fibrin (Martius Scarlett Blue stain: positive) were occasionally found attached to the serosa, 
mesothelial cells were not readily identifiable and the Masson trichrome stain showed that the capsular 
connective tissue layer in these areas was disorganised and split into irregularly arranged 
discontinuous fibres (Figure 2E). 
The immunohistological examination of CD-1 mice euthanased at 3 h after dosing showed that 
neutrophils infiltrating the areas of hepatocyte necrosis expressed both the proinflammatory cytokines 
TNF-α and IL-6. At 24 h post dosing, increased numbers of PCNA-positive, proliferating hepatocytes 
were present in the periphery of the necrotic areas, indicating the onset of hepatocyte regeneration 
(Figure S1, supplementary data). The lack of cleaved caspase 3 expression in degenerate hepatocytes 
confirmed necrosis as the mode of hepatocyte death (data not shown). 
The ultrastructural examination confirmed both the loss of mesothelial cells and acute subcapsular 
hepatocyte necrosis in affected areas (Figure 3). 
In 40% (6/15) of the mice where abdominal organs were examined in addition to the liver, slight to mild 



































































the diaphragm and the abdominal wall (Figure S2, supplementary data). This was occasionally 
associated with mild focal haemorrhage and scattered myofibre degeneration in the latter. 
 
3.2 In vitro studies 
In order to corroborate our in vivo observations, human and murine hepatoma cell lines were exposed 
for 5, 8 and 24 h to gradual concentrations (0 to 30%) of PEG-400, diluted in isotonic saline. A dose-
dependent reduction of cell viability was detected by (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTS) and ATP assays in both cell lines with both assays even at the 
lowest dilution tested (2.5%), confirming the cytotoxic effect of PEG (Figure S3, supplementary data).
 
DISCUSSION 
The present study reveals the cytotoxicity of PEG-400 at high concentrations. When administered ip at 
a high dose to mice without prior dilution, PEG-400 has an apparent cytopathic effect on mesothelial 
cells and hepatocytes immediately beneath the serosal surface, leading to necrosis and a neutrophilic 
inflammatory response. In vivo data are paralleled by the evidence of hepatocytotoxicity exerted by 
PEG-400 on permanent cell lines derived from human and murine neoplastic hepatocytes, even at very 
low concentrations.  
Data concerning the safety of parenteral administration of PEG products are scant. A maximum dilution 
of 30% is recommended when PEG is administered intravenously to humans and dogs, as higher 
concentrations may cause haemolysis (Rowe et al., 2009; Li et al., 2011). It remains to be clarified 
whether this is also a consequence of the hydrophilic properties of PEG-400 which are in our study the 
apparent cause for the local recruitment of fluid into the peritoneal cavity early (1 and 3 h) after its ip 
administration. However, it may be hypothesised that PEG-400 exerts a local cytotoxic effect on 
mesothelial cells and hepatocytes within the first minutes after administration, prior to dilution of the 
inoculum by the fluid recruited into the peritoneal cavity. 
This study provides a preliminary data for preclinical toxicological studies using PEG-400 as a vehicle 
for intraperitoneal administration. However, further investigation is needed to clarify whether the low 



































































findings analogous to those observed in vivo with ip administration of undiluted PEG and to compare 
the safety of PEG with various molecular weights. Recent research on hepatotoxicity has focused on 
the development of new reliable and specific biomarkers of hepatic injury, which should be able to 
sensitively predict toxicity in preclinical models. PEG injury could lead to enhanced damage when 
administered with test compounds, potentially complicating a mechanistic interpretation. This current 
work underscores the critical role of histopathology as a compulsory tool for the correct interpretation of 
biomarker level variations and stresses once again the importance of research into new, mechanism-
specific biomarkers of hepatocellular injury. 
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Figure and Table legends 
 
Figure 1. A. Box-plots for ALT levels measured in the plasma obtained at terminal bleeding of mice at 
different time points after ip PEG-400 (4 mL/kg) administration. Numbers of mice evaluated in each 
cohort are displayed in brackets on the legend of the x axis. Values on the ordinate are the natural 
logarithm of the actual ALT measurement Dotted lines represent mean ALT reference values for male 
(top line, 120 U/L, SD: 106.7 U/L) and female (bottom line, 62 U/L, SD: 54.8 U/L) CD-1 mice. B. 
Correlation between ALT and circulating miR-122 levels. miRNA levels were determined in 12 CD-1 
mice administered PEG-400 (4 mL/kg) ip and euthanased 5 or 8 h after dosing. Values on both axes 
are expressed as the base-10 logarithm of the actual measurements. 
 
Figure 2. Histological changes in the liver of mice after ip administration of PEG-400 (4 mL/kg). A to C. 
Hepatic subcapsular necrosis (arrows) grade 1 (A, CD-1 mouse, 5 h post treatment), (B, C57/B6 
mouse, 5 h post treatment) and grade 4 (C, C57/B6 mouse, 24 h post treatment), characterised by 
coagulative necrosis of hepatocytes, neutrophil infiltration and blood extravasation; haematoxylin and 
eosin stain, 20 x. D and E CD-1 mouse, 8 h post treatment. The Glisson’s capsule represents one 
dense continuous line (arrow) in unaffected areas (D); in areas overlying a layer of hepatocyte necrosis 
(E) the capsule is disrupted and appears as a fragmented undulating blue line (arrowheads); Masson 
trichrome stain, 20 x.  
 
Table 1. Incidence and severity of hepatic subcapsular necrosis in mice at different time points (1, 5, 8 
and 24 h) after ip PEG-400 administration at a dose of 4 mL/kg, based on the histological evaluation of 
several liver sections of each animal.  
 
Figure 3. Ultrastructural changes in the liver capsule and underlying parenchyma of a CD-1 mouse, 3 h 
post ip administration of PEG-400 (4 mL/kg) A) The hepatocytes immediately beneath the capsule are 
vacuolated or necrotic, whereas the underlying hepatocytes (below the dotted line) appear unaltered 





































































hepatocytes. B) Higher magnification of the transition (dotted line) between a necrotic (top) and viable 
(bottom) hepatocyte. The hepatocyte undergoing necrosis exhibits dilated mitochondria (arrows) and in 
the nucleus (arrowhead) disintegration of the nuclear membrane and the nucleolus and clumping of 
chromatin. C) Mesothelial cells are lost (*) and the capsule is expanded and infiltrated by neutrophils 
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Subcapsular necrosis 1 h 5 h 8 h 24 h 
Grade 0 5 12 6 5 
Grade 1 0 4 9 5 
Grade 2 0 9 7 3 
Grade 3 0 3 3 3 
Grade 4 0 0 0 2 
% affected mice 0/5 44 (16/28) 75 (19/24) 72 (13/18) 
Average severity 0 1.11 1.21 1.56 
 
Table 1.docx








Click here to download Figure: Figure  1.docx
Figure 2.tif
Click here to download high resolution image
Figure 3.tif
Click here to download high resolution image
Pellegrini Supplementary (2).docx
Click here to download Supplementary Material: Pellegrini Supplementary (2).docx
Conflict of Interest.pdf







